Introduction
Ghrelin is a hormone found mainly in the stomach. the actions of ghrelin are primarily orexigenic-to stimulate appetite, increase energy stores and promote the deposi tion of adipose tissue. the ability of ghrelin to modulate energy balance and alter intestinal motility suggests that modification of ghrelin signaling pathways might be bene ficial for patients with gastrointestinal disorders or obesity. this hypothesis has led to the development of agents that pharmacologically modulate ghrelin receptors. this review discusses key issues in relation to the role of ghrelin in gastrointestinal motor function, obesity and the meta bolic syndrome. alterations in levels of ghrelin that are observed following bariatric surgery and drug manipula tions are also discussed, and the effects of ghrelin agonists and a new class of therapeutic agents, the smallmolecule ghrelinreceptor antagonists, are described.
Function and metabolism of ghrelin

Function
Ghrelin is a 28amino acid peptide that is acylated at its third serine residue with an octanoyl group. the amino acid sequence of ghrelin is 36% homologous with that of motilin, a hormone with a known ability to modulate gastric motor activity. 1 Ghrelin was origi nally identified in 1999 as the endogenous ligand of the growthhormone secretagogue receptor 1a (GHsr1a), 2 a Gproteincoupled receptor that was first cloned from hypothalamic tissue. 3 GHsr1a was the prototype of a class of receptors that were of particular interest because of their ability to induce the release of pituitary growth hormone following their activation by synthetic pep tides. the ligands for these receptors were collectively termed the growthhormone secretagogues. 4 By acting on their corresponding receptor, these ligands directly stim ulate growthhormone release from the pituitary gland, rather than via the conventional pathway mediated by growthhormonereleasing hormone. For the purpose of clarity, this review uses the terms 'ghrelin receptor' to refer to the GHsr1a, 'ghrelin agonist' to refer to exo genous GHsr1a receptor ligands, and 'ghrelin antagonists' for antagonists of the GHsr1a receptor.
in addition to stimulating growthhormone release, the administration of exogenous ghrelin induces a robust feeding response 5 and influences energy homeostasis. Ghrelin also exerts effects on the adrenal gland and the pituitary-gonadal axis and is involved in regulation of the immune system, osteoblast function, the cardio vascular system and neoplastic cell proliferation in several types of cancers (for example, lung, breast, pituitary and thyroid [ Figure 1] ). [6] [7] [8] Ghrelin also significantly increases expression levels of insulinlike growth factor i (iGFi) and fatfree mass in elderly individuals, which suggests that this hormone might have a role in the reversal of sarco penia. 9 the focus of this review, however, is the effects of ghrelin on gastrointestinal function, glycemic control and the metabolic syndrome, and properties relating to other actions of ghrelin will not be discussed further.
www.nature.com/nrgastro reviews location of ghrelin and its receptor Ghrelin has been identified in all human tissues studied, but 80-90% of ghrelin is located in the stomach, where it is produced by ghrelinproducing endocrine cells. endocrine cells located in the human oxyntic mucosa include enterochromaffin cells, which produce 5hydroxytryptamine or histamine, somatostatin producing cells (D cells), and X/a cells, which secrete unknown products. the ghrelinproducing cells in the stomach resemble X/a cells, and in fact, some X/a cells may produce ghrelin. 10 a small ghrelin 'reservoir' is located in the central nervous system, namely in the arcuate nucleus and in a group of neurons that are located adjacent to the third ventricle in the hypothalamus. Both of these central sites are involved in the regulation of appetite. 11, 12 the ghrelin receptor is also widely expressed. in the brain, it is predominantly expressed in the arcuate nucleus, and peripherally, it has been identified in the stomach, intestine and pancreas. 3, 13 Circulating ghrelin probably crosses the blood-brain barrier to reach its central targets.
14 alternatively, ghrelin might indirectly activate neurons in the arcuate nucleus, possibly via vagal signaling. 15 However, findings from studies in patients who have undergone vagotomy indicate that induc tion of growthhormone secretion by ghrelin might not involve afferent vagal stimulation, and thus the mechanisms by which ghrelin exerts its actions are not completely understood. 16 other products of the ghrelin gene the human ghrelin gene is located on chromosome 3p and comprises five exons and three introns; the first exon is noncoding. Ghrelin is derived from the ghrelin gene by alternative splicing and extensive posttranslational enzymatic modification from the sequential precursor peptides, preproghrelin and proghrelin. 17 in addition to ghrelin, other peptides are also produced by alterna tive splicing and posttranslational modification of the ghrelin gene product. Desacyl ghrelin is produced from the cleavage of proghrelin, and is the major circulating form of ghrelin. this peptide lacks the octanoyl group, which is essential for binding to the ghrelin receptor. 18 Cleavage of proghrelin also produces a 66amino acid tail, which may either circulate as a fulllength peptide (cghrelin), 19 or be processed to produce small peptides, including a 23amino acid peptide called obestatin.
obestatin was first identified in mice by Zhang et al., 20 who described the inhibitory effects of this peptide on food intake, gastric emptying in vivo and jejunal muscle contractions in vitro. another study, however, was unable to replicate these findings. 21 Furthermore, no evidence of circulating obestatin peptides in humans and rats, or in rat tissue, has been found. 21, 22 ghrelin metabolism as mentioned earlier, almost 90% of ghrelin circulates in the blood as desacyl ghrelin. this peptide is not octanoyl ated and, therefore, does not bind to the ghrelin receptor. instead, it binds to an asyetuncharacterized recep tor. 23 studies have demonstrated subtle and sometimes contra dictory biological actions of desacyl ghrelin in the control of food intake, 24 glucose 25 and lipid 26 metabolism, gastrointestinal motor function 27 and cellular prolifera tion. 28 these effects usually oppose or modify the actions of ghrelin.
the enzyme that catalyzes the octanoylation of desacyl ghrelin at ser3 to produce active ghrelin was identified in 2008 as ghrelin oacyltransferase (Goat), 29 a member of the superfamily of membranebound oacyltrans ferases. the discovery of Goat provides a putative, selec tive target through which to inhibit the biological actions of ghrelin by prevention of its activation by octanoylation. Goat inhibitors might, therefore, prevent the develop ment of dietinduced obesity or be used to treat patients with type 2 diabetes by preventing the inhibi tion of insulin secretion and sensitivity by ghrelin. 30 Fluctuations in circulating levels Plasma levels of ghrelin increase with prolonged fast ing-an effect that is reversed by an intragastric infu sion of glucose. 31 Circulating levels of ghrelin surge shortly before scheduled meals and are suppressed by ingested nutrients. Carbohydrates have the greatest sup pressive effect, followed by proteins, with fats having the least effect on ghrelin levels. 32 the control of pre prandial ghrelin secretion remains incompletely understood; however, the actions of sympathetic nerves, endothelin and secretin might be involved. 33 Postprandial ghrelin suppression has been docu mented in many animal species and in human adults, but not in children. 34 the mechanism by which ghrelin is suppressed postprandially is also unclear. Postprandial ghrelin suppression seems to result, at least in part, from neurally transmitted intestinal signals that are not medi ated through vagal pathways and are augmented by the presence of insulin. suppression of plasma ghrelin levels is observed after administration of oral or intravenous glucose loads in healthy individuals and in patients with type 2 diabetes mellitus after intake of a meal, but not after gastric distention. 35, 36 However, postprandial ghrelin suppression was not observed in patients who reviews had undergone subdiaphragmatic vagotomy or total gastr ectomy. 36 these data suggest that in healthy indivi duals, postprandial ghrelin suppression may be partially mediated by vagal mechanisms, since suppression was absent with vagotomy. However, a nongastrointestinal mechanism probably explains the suppression of ghrelin observed after intravenous administration of glucose. the expression of ghrelin receptors in the stomach, hypothalamus and pituitary gland is also dependent on the satiety and energy status of an individual. 37 
Regulation of energy homeostasis
Ghrelin acts as an orexigenic factor, independent of the degree of satiety 38 and growthhormone secretion 39 in many species, including humans. 40 the orexigenic actions of ghrelin are believed to be mediated at least in part via central activation of neuropeptide Y pathways, 41 which causes a shortterm increase in food intake.
in addition, ghrelin can act as a mediumterm and longterm regulator of energy homeostasis by increasing fat deposition and inducing a positive energy balance. Ghrelin levels increase during diet or diseaseinduced weight loss. 42 obese children and adults have lower fasting ghrelin levels and exhibit smaller postprandial changes in ghrelin levels than do agedmatched con trols of a normal weight. 43 Ghrelin serum levels are also inversely correlated with age and concen trations of serum insulin. 44 in contrast with studies in obese people, a study in mice by asakawa et al. demonstrated that fasting expression levels of ghrelin messenger rna (mrna) in the mouse stomach were increased by a highfat diet. 45 in this study, ghrelin reportedly induced adiposity in a dosedependent manner, elevated blood glucose and decreased insulin production. 45 Ghrelin also elevated leptin mrna levels and reduced expres sion levels of resistin mrna. 45 thus, modulation of serum ghrelin by fat intake is speciesdependent, but the orexigenic effects of ghrelin are consistent in mice and humans.
in a randomized, placebocontrolled trial, strassburg et al. administered either human ghrelin or one of two ghrelin agonists (Bim28125 and Bim28131) to rats by continuous subcutaneous infusion for 2 weeks in doses either intended to mimic physiological doses, or at high, 'pharmacological' doses. 46 Physiological doses had no effect on body weight or body composition. the high doses of ghrelin and ghrelin agonists induced weight gain in rats by promotion of fat deposition and, to a lesser extent, leanmass gain. all the abovedescribed medium term and longterm effects of ghrelin are thought to be mediated via agrPmediated pathways in the hypo thalamus. of note, neuropeptide Y and agrP pathways interact in the hypothalamus to control energy homeo stasis. 47 the ghrelin system also interacts with other complex brain-peptide pathways to control food con sumption and energy homeostasis; these relationships are reviewed in detail elsewere. 48 Regulation of gastric motility the potential therapeutic effects of ghrelin and its ago nists have been investigated in three clinical scenarios. First, for the treatment of gastrointestinal diseases, such as postoperative ileus and gastroparesis; 49 second, as an alternative to exogenous growthhormone administra tion in children or to enhance growthhormone secretion with an aim to increase lean mass in otherwise healthy adults; 9,50 third, to control appetite and eating disorders and in patients with cardiac cachexia. 50 Figure 1 | Ghrelin affects multiple systems. Ghrelin is secreted mainly by the stomach, but has effects in multiple areas, including the CNs, the immune system, the adrenal gland and the cardiovascular system. Ghrelin can also affect the proliferation of osteoblasts and neoplastic cells. Abbreviations: CNs, central nervous system; GH, growth hormone. 
CNS
GH secretion reviews the rationale for using ghrelin to treat gastrointestinal diseases is based mainly on its effects on gastric motil ity. the effects of an intravenously administered ghrelin agonist, tZP101, were evaluated in a phase i trial in humans, which showed promising results in terms of its safety and its pharmacokinetic and pharmaco dynamic profiles. 51 in animal studies, tZP101 accelerated the gastric emptying of liquids in rats. 52 Phase ii trials are in progress to investigate the effects of tZP101 in patients with postoperative ileus or severe gastro paresis. another ghrelin agonist that is administered orally, tZP102, is also under evaluation for the treatment of chronic gastroparesis. 53 administration of a growthhormone secretagogue and a ghrelin mimetic (mK677) to healthy elderly indivi duals increased levels of growth hormone and iGFi to those observed in healthy young adults. the treatment was well tolerated and increased fatfree mass; 9 however, no benefit to quality of life was noted. in addition, mK677 increased insulin resistance and blood glucose levels. the results from this study should, however, be interpreted with caution, because of the small sample size and relatively short duration of treatment.
the potentially increased risk of cancer associated with chronic growthhormone secretagogue therapy is cause for concern. Ghrelin and its receptors are expressed in several tumor and neoplastic cell lines, which suggests a possible autocrine or paracrine role for ghrelin in neo plasm development. 54 moreover, activation of the growth hormone-iGFi axis may predispose an indivi dual to cancer, because the iGF receptor has a role in cancer development, growth and metastasis. 55 on the other hand, a reassuring finding is that in elderly indivi duals, mK677 not only increased the production of iGFi, but also modestly increased production of the iGFibinding proteins, which act to inhibit the prolifera tive effects of iGFi. in elderly mice, administration of a growth hormone secretagogue actually inhibited metastatic tumor growth. 56 Ghrelin also exerts anti proliferative effects in various human tumor cell lines, derived from thyroid cancer, smallcell lung cancer, and breast carci noma; however, ghrelin exerts proliferative actions in prostate, hepatoma and pancreatic carcinoma cell lines. 57 longterm studies are, therefore, required for all ghrelin agonists, with careful selection of patients before initia tion of therapy to enable a full examination of the safety profile of this class of therapeutic agents.
effects of ghrelin agonists on gastric motility
Findings from studies in animals have revealed that ghrelin stimulates gastric motor function by acting at several levels: by vagal signaling, directly within the enteric nervous system, or by effects on vagal function within the central nervous system after crossing the blood-brain barrier (Figure 2 ). intravenous administra tion of a 0.2 μg/kg dose of exogenous ghrelin to healthy individuals does not increase levels of circulating growth hormone above those observed physiologically. 58 this dose of ghrelin is, therefore, considered to be a physio logical dose; however, most reported studies have used pharmacological doses that are 100-1,000 times higher than physiological doses. 58, 59 Studies in healthy volunteers a study by tack et al. used an antroduodenal mano metry catheter together with a barostatically controlled balloon that was placed in the gastric fundus to investi gate the effect of ghrelin administration on upper gastro intestinal motility in nine healthy individuals. 60 the administration of 40 μg ghrelin as an intravenous infusion over a 30 min interval induced premature onset of phase iii of the migrating motor complex, and increased proximal gastric tone. these effects are similar to those induced by intravenously administrated motilin. However, given the lack of crossreactivity in cell lines that express the receptors for both peptides, 61 the actions of ghrelin seem to be independent of the actions of motilin or its receptors.
our group has measured gastric volume following the administration of ghrelin to healthy volunteers by using single photon emission Ct (sPeCt). 58 intravenous bolus administration of 0.33 μg/kg ghrelin produced physiological levels of circulating growth hormone, but resulted in only a slight, albeit significant, reduction in Gastric accommodation reviews fasting gastric volumes compared with those measured in patients given a placebo. Ghrelin administration had no significant effect on the gastric emptying of solids or gastric accommodation volumes. the fixed dose administered to patients in the study by tack et al. 60 was approximately twice the physio logical dose admin istered in the sPeCt study. 58 thus, the contrasting results obtained by these two studies could arise from the differ ent ghrelin doses that were administered. of note, an in vitro study that investigated the effects of ghrelin on isolated gastric smoothmuscle strips obtained from diabetic mice with gastroparesis also failed to demonstrate a role of ghrelin in the induction of muscle contractions. 62 Studies in patients with gastroparesis the potential of ghrelin to act as a prokinetic drug for the treatment of gastroparesis has been tested in several clinical studies (table 1) . in one doubleblind, placebo controlled, crossover study, 10 patients with diabetes and symptoms of gastroparesis received an intravenous infu sion of saline or ghrelin (5 pmol · kg -1 /min) for a period of 2 h on two separate occasions. 63 the rate of gastric emptying after a ricepudding meal was recorded using serial abdominal ultrasound scans. Ghrelin increased gastric emptying in seven of the 10 patients from 30 ± 6% emptied 2 h after administration of saline to 43 ± 5% after treatment with ghrelin. 63 other studies have investigated the effects of ghrelin administration in patients with idiopathic and diabetic gastroparesis and in patients with gastroparesis that arose secondary to vagotomy. these studies demonstrated a similar acceleration of gastric emptying to that described above. [64] [65] [66] However, some studies have reported mixed results or that administration of ghrelin to patients with gastroparesis had no effect on gastric emptying. 63, 65 all the abovedescribed studies have used small sample sizes and employed different methods to measure gastric emptying. the conflicting results obtained in these clini cal studies [63] [64] [65] [66] might, therefore, be explained by varia tions in the doses of ghrelin administered or by other methodological differences, such as the method used to measure gastric emptying (table 1) . in general, data suggest that stimulation of ghrelin receptors by use of high pharmacological doses of ghrelin might acceler ate gastric emptying, induce contraction of the human gastric fundus and/or reduce fasting gastric volume.
the effect of ghrelin agonists on symptoms in patients with gastroparesis, however, requires further study. murray et al. did not observe any increase in bloating, hunger or nausea following the administra tion of ghrelin, 63 while tack et al. demonstrated that Future studies will need to compare the benefits and potential risks of using ghrelin agonists with other pharmacological agents for the treatment of gastric motility disorders. For example, the new class of 5hydroxytryptamine receptor 4 (5Ht 4 ) agonists (for example, prucalopride and tD5108), have greater selec tivity for 5Ht 4 receptors relative to KCNH2 channels (also known as HerG channels), and seem to stimulate gastric emptying. the selectivity of these agonists indi cates they should have improved safety from a cardiac perspective compared with previous 5Ht 4 agents, such as cisapride. the relative effectiveness of ghrelin agonists and this new class of compounds remains to be elucidated.
ghrelin antagonists and gastric motility
Findings from a study in which ghrelin administration stimulated the production of growth hormone to levels within the normal range suggest that, at these physio logical levels, ghrelin does not significantly alter gastric accommodation or emptying, but does have a moderate effect on fasting gastric volumes. 58 these data suggest that the ghrelin receptor does not have a pivotal role in the control of baseline gastric function and, therefore, that inhibition of ghrelin receptors by use of ghrelin antago nists would not be predicted to considerably impair gastric motor function. studies that have investigated the effects of administration of a new class of agent-the smallmolecule ghrelinreceptor antagonists-to animals support this interpretation; only very high doses of these agents delayed gastric emptying. By contrast, low doses of ghrelin antagonists had effects on body weight, but did not impair gastric emptying.
45,67
Regulation of glucose homeostasis
Insights from studies with ghrelin agonists experimental studies in humans and animals support a direct role for ghrelin in the regulation of glucose homeostasis by activation of ghrelin receptors located in the pancreas (Figure 2 ). Ghrelin and its receptor are both expressed in pancreatic islet cells. 68, 69 Ghrelin has been demonstrated to suppress insulin secretion in vitro and in vivo and cause an increase in plasma levels of glucose in rodents 70 and in humans. 71 one study investi gated the effects of intravenous ghrelin administra tion to patients who had previously undergone gastr ectomy or vago tomy. Compared with patients who received an intra venous infusion of saline, the administra tion of ghrelin during a hyperinsulinemic euglycemic clamp procedure reduced endogenous insulin secretion (demon strated by reduced Cpeptide levels) and reduced the rate of glucose disposal. 72 Chronic administra tion of small molecule ghrelin agonists to healthy, elderly indivi duals induces hyperglycemia and insulin resistance. 73 Conversely, ablation of ghrelin signaling improves glucose tolerance and enhances insulin secretion in leptindeficient ob/ob mice. 74 Despite findings from several studies that support a role for ghrelin in the control of glucose homeostasis, conflicting reports also exist with regard to differences between species and in feeding status. For example, a study performed in sheep aimed to define the role of ghrelin further in the control of glucosemediated insulin secretion in relation to feeding status and energy balance. 75 a hyperglycemic clamp was established with a continuous titration of glucose to examine the effect of ghrelin on the glucoseinduced insulin response during fasting and after feeding. in the fasting state, administra tion of a synthetic ghrelin antagonist significantly enhanced glucoseinduced insulin secretion; this finding is consistent with observations in small animals, such as rodents, in which ghrelin reduces insulin secretion. 70 However, in the fed state, intravenous administration of synthetic, ovine ghrelin during a hyperglycemic clamp also significantly enhanced glucoseinduced insulin secretion-an effect that was suppressed by subsequent treatment with a ghrelin antagonist. these data suggest that ghrelin acts to inhibit or stimulate glucoseinduced insulin secretion in the fasting and fed states, respectively. these actions of ghrelin are probably directly medi ated by ghrelin receptors located in the pancreas. this hypothesis of the mechanism of ghrelin action is sup ported by a series of experiments performed in normal, gastr ectomized and ghrelinknockout mice, which demonstrated that ghrelin derived from the pancreatic islet cells is a physiological regulator of glucoseinduced insulin release (Figure 3 ). 76 the majority of studies that have explored the role of desacyl ghrelin in glucose metabolism have found that this alternative product of the ghrelin gene counteracts or modifies the actions of ghrelin. as mentioned earlier, the receptor to which desacyl ghrelin binds has not yet been identified; however, findings from studies that used isolated mouse and rat pancreatic islet cells suggest that desacyl ghrelin regulates glucose metabolism without affecting hormone secretion by the pancreas. several lines of evidence indicate that desacyl ghrelin counteracts the effects of ghrelin on insulin secretion. administration of desacyl ghrelin to isolated islet cells of rodents at a 10fold greater concentration than that of ghrelin inhib its the ability of ghrelin to reduce insulin secretion. 25 intravenous administration of desacyl ghrelin to normal, healthy individuals completely blocks the hyper glycemic effects of a bolus ghrelin injection. 77 Finally, desacyl ghrelin inhibits glucose output from isolated pig hepato cytes and counteracts the stimulatory effect of ghrelin on hepatocyte glucose output. 78 Ghrelin also seems to promote the survival of pancre atic βcells by mechanisms other than ghrelinreceptor activation; administration of ghrelin inhibited apoptosis in a pancreatic βcell line via maPK-Pi3K pathways. 79 Ghrelin and desacyl ghrelin also promoted proliferation and inhibited βcell apoptosis in a βcell line and in human reviews islets of langerhans via camP-PKa, erK1-erK2, and Pi3K-akt signaling pathways. 28 Insights from animal models the investigation of ghrelin and ghrelinreceptor knock out mice has not provided clear insight into the effect of ghrelin receptors on body weight. For example, the administration of exogenous ghrelin to ghrelinreceptor knockout (GHsr -/-) mice did not stimulate appetite or growthhormone release. 80 normal 'wildtype' , ghrelin knockout (ghrelin -/-) and GHsr -/-mice do not signifi cantly differ in terms of body weight or growth rate. 80 Deletion of the ghrelin or ghrelinreceptor gene did not prevent dietinduced obesity or weight gain after weight loss. 81 weight loss with caloric restriction was identical between wildtype, ghrelin -/-and GHsr -/-knockout mice, despite the fact that blood glucose levels under caloric restriction were lower in knockout mice than they were in wildtype mice. 81 However, ghrelin -/-mice have increased glucoseinduced insulin secretion and improved peripheral insulin sensitivity, which is consis tent with the demonstrated ability of ghrelin to reduce insulin secretion. 74 Findings from knockout studies can be misleading, however, because compensatory mechanisms might be switched on to replace the function of the removed gene. Compensatory mechanisms for appetite and weight regulation probably account for some of the unexpected findings from the abovedescribed knockout studies. to summarize the findings from this somewhat conflicting pool of data, ghrelin seems to be important for glucose homeostasis and insulin sensitivity, but might not be important for the regulation of growth and body weight. the presence of compensatory mechanisms that regulate appetite and weight cannot be excluded.
Insights from studies with ghrelin antagonists Pharmacological antagonism of pancreatic ghrelin receptors in rats with dietinduced glucose intolerance enhanced insulin release and normalized glycemic control. 76 a growing body of evidence from studies in rodents indicates that smallmolecule ghrelin receptor antagonists enhance glucose homeostasis, insulin release and sensitivity, and induce weight loss in situa tions of energy excess. the authors of a comprehensive study in rats, which involved in vivo and in vitro investigations, reported that the ghrelin antagonist, Yil870, com pletely blocked the dosedependent, ghrelininduced suppression of insulin secretion from dispersed rat islet cells. 67 a single, oral dose of Yil870 improved glucose homeostasis during an intra peritoneal glucose toler ance test in rats. 67 the effects of Yil870 were similar to those of a positive control-liraglutide, an antagonist of the human glucagonlike peptide 1 receptor, which also normalizes blood glucose. the improvement in glucose homeostasis observed after administration of Yil870 was accompanied by increased insulin secre tion. on the other hand, the effect of Yil870 on fasting glucose was less than that induced by a rapidonset sulfonylurea, nateglinide. 67 this finding suggests that the smallmolecule ghrelinreceptor antago nists may be less effective inducers of isletcell insulin secretion during fasting than they are post prandially. Ghrelin receptor antagonists such as Yil870 might, therefore, act speci fically to reduce glucose in the fed state, but reduce the risk of hypo glycemia in the fasted state. the same study also reported that daily oral administration of Yil870 led to reduced food intake and resulted in weight loss of up to 15% of pretreatment weight, caused by the selective loss of fat mass in dietinduced obese mice. 67 Comparison with the cannabinoid 1 receptor antagonist, rimonabant, demonstrated that Yil870 induced a longerlasting weight reduction and a more sustained reduction of food intake. Findings from pairfeeding experiments indicated that the weight loss induced by Yil870 was largely a consequence of reduced food intake. 67 at the highest tested dose (10 mg/kg), Yil870 caused a modest delay in gastric emptying in obese mice. the magnitude of this effect was comparable to that induced by the positive control, the glucagonlike peptide 1 analog, exendin4. at doses that improved gly cemic control and weight loss, however, Yil870 had no effect on gastric emptying. these findings indicate that reviews delayed gastric emptying is not required for Yil870 to induce weight loss. 67 the influence of ghrelin antagonists on energy balance has also been evaluated by asakawa et al. in lean mice, dietinduced obese mice, and ob/ob mice. 45 repeated administration of a smallmolecule ghrelinreceptor antagonist decreased weight gain and improved glycemic control in the leptindeficient and dietinduced obese mice-an effect that was not observed in the lean mice. the authors concluded that ghrelin activity is closely related to excess weight gain, adiposity and insulin resistance, particularly in situations of energy excess (for example, in animals fed a highfat diet). 45 together, the findings from these studies suggest that ghrelin antagonists might have potential therapeutic applica tions for the treatment of patients with type 2 diabetes or metabolic syndrome.
Effect of bariatric surgery on ghrelin surgical approaches to manage morbid obesity result in gastric restriction and/or intestinal malabsorp tion. Procedures that cause gastric restriction include laparo scopic verticalbanded gastroplasty, laparoscopic adjustable gastric banding and sleeve gastrectomy. 82 Procedures that cause intestinal malabsorption include bilio pancreatic diversion and biliopancreatic diversion with a duodenal switch. the rouxenY gastric bypass procedure has features of both gastric restriction and intestinal malabsorption. 83 the longterm efficacy of laparoscopic adjustable gastric banding compared with conventional pharmaco logical and lifestyle interventions for reducing weight in patients with mild to moderate obesity was demon strated in a randomized, controlled trial. 84 in this study, the weight loss achieved by the conventional and surgi cal interventions after 6 months was identical; patients in both groups lost 13.8% of their pretreatment weight. However, while the surgicalintervention group con tinued to lose weight-patients in this group achieved a mean loss of 21.6% of their pretreatment weight after 2 years-the nonsurgical intervention group progres sively regained weight, which resulted in a mean weight loss of just 5.5% after 2 years. the prospective, controlled swedish obese subjects study investigated the efficacy of bariatric surgery compared with that of pharmacological interventions for weight loss. this trial had a followup period of 12 years, and reported similar findings to those described above. 85, 86 this study found that body weight stabilized 8-9 years after all types of surgical interventions investi gated. the greatest weight reductions were achieved by gastric bypass, while the least effective method was laparo scopic adjustable gastric banding.
the effects of diet and rouxenY gastric bypass on the levels and diurnal profile of endogenous ghrelin was investigated by Cummings et al. 87 Diet induced an average loss of 17% of initial body weight after 6 months, and was associated with a significant increase in plasma levels of ghrelin over a 24 h period. By contrast, despite a loss of 36% of pretreatment body weight in patients after rouxenY gastric bypass, levels of plasma ghrelin were significantly lower in this group of patients than in normal weight controls and weightmatched, obese controls. Furthermore, rouxenY gastric bypass abol ished the normal, mealrelated fluctuations and diurnal rhythm of plasma ghrelin levels. these results do not enable a straightforward interpretation of the relationship between levels of ghrelin and weight loss. the increased plasma levels of ghrelin in the diet group would be expected to induce an increase in appetite and weight gain, rather than weight loss. whether the reduced plasma levels of ghrelin observed after rouxenY gastric bypass resulted from reduced contact between gastric mucosal mass and food, or contributed to the reduction in weight after surgery, is unclear. the important influence of residual gastric mass on postoperative ghrelin levels is illustrated by the fact that ghrelin levels do not signifi cantly change in patients after laparoscopic adjustable gastric banding. 88 other alterations that occur in levels of gut peptides and hormones after bariatric surgery may also contribute to weight loss. le roux et al. evaluated the effect of the rouxenY gastric bypass procedure on levels of various enteric peptide hormones, including ghrelin, glucagon likepeptide 1 and peptide YY. in line with results from the study by Cummings et al., le roux et al. reported that levels of ghrelin were typically lower in patients after rouxenY gastric bypass than they were before surgery. High postoperative levels of glucagonlikepeptide 1 and peptide YY were associated with increased weight loss. 89 How changes in levels of these hormones that occur after bariatric surgery alter signaling pathways to control body weight is not yet known.
of note, although findings from several studies suggest that levels of ghrelin and other hormones, such as glucagonlikepeptide 1 or peptide YY, are altered by diet or surgeryinduced weight loss and might have implications for the treatment of obesity, 89 these studies cannot conclusively differentiate association from causation. experimental studies that involve the administration of antagonists and robust clinical trials are necessary to explore the role of these substances further in the regulation of weight loss. Development of smallmolecule ghrelin antagonists for human studies will enable such mechanistic studies to be conducted in the future.
Conclusions
the modulation of ghrelin and its receptors will produce a new therapeutic armamentarium with poten tial therapeutic benefits in multiple systems. Ghrelin agonists may be effective for the treatment of gastro intestinal motility disorders, such as gastroparesis and postoperative ileus. Ghrelin acts directly on pancreatic islet cells to decrease insulin secretion during fasting and, in most models, increases levels of insulin after reviews feeding. Ghrelin antagonists, therefore, have the poten tial to improve glycemic control, suppress appetite and induce weight loss. Glycemic control may also be improved by the administration of Goat inhibitors, to prevent the generation of active ghrelin. Gastric capa city and emptying are unlikely to be markedly altered by ghrelin antagonists. the ability of ghrelin antago nists to induce weight loss should, therefore, be tested in clinical trials on individuals with obesity and the metabolic syndrome.
Review criteria
PubMed was searched in October 2008 using the terms "ghrelin", "obesity", "metabolic syndrome", "smallmolecule ghrelin-receptor antagonists" and "glucose regulation", both alone and in combination. englishlanguage papers and full reports published since 1999 and reviews published until 2008 were included with a focus on results from studies in humans and experimental animals.
